CALCA and cutaneous mastocytosis: Fremanezumab, a fully humanized monoclonal antibody (IgG2a) that selectively targets calcitonin gene-related peptide (CGRP), is efficacious in preventing chronic migraine (CM), but its effectiveness in patients who have failed previous preventive medications is unknown.